Paul Mahon Sells 11,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 11,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 24th. The stock was sold at an average price of $513.18, for a total value of $5,644,980.00. Following the completion of the transaction, the executive vice president owned 36,781 shares of the company’s stock, valued at approximately $18,875,273.58. This represents a 23.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

United Therapeutics Trading Down 1.3%

NASDAQ UTHR opened at $496.19 on Wednesday. The stock has a market cap of $21.37 billion, a P/E ratio of 18.80, a PEG ratio of 4.99 and a beta of 0.86. The company’s fifty day simple moving average is $474.25 and its 200-day simple moving average is $391.62. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $519.99.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The firm had revenue of $799.50 million for the quarter, compared to the consensus estimate of $812.87 million. During the same quarter in the previous year, the firm posted $6.39 EPS. The firm’s quarterly revenue was up 6.8% on a year-over-year basis. On average, research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on UTHR shares. Wells Fargo & Company raised their price objective on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research report on Monday. HC Wainwright lifted their price target on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Jefferies Financial Group reiterated a “buy” rating and set a $575.00 price objective on shares of United Therapeutics in a research note on Wednesday, November 19th. Finally, Royal Bank Of Canada raised their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a report on Thursday, October 30th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $505.00.

Hedge Funds Weigh In On United Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Chung Wu Investment Group LLC bought a new stake in United Therapeutics during the second quarter valued at $29,000. WealthCollab LLC lifted its position in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the last quarter. Rakuten Securities Inc. boosted its holdings in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares during the period. Wilmington Savings Fund Society FSB grew its position in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares during the last quarter. Finally, Abich Financial Wealth Management LLC bought a new stake in shares of United Therapeutics during the 3rd quarter valued at about $44,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.